IMPORTANT ANNOUNCEMENT

PLEASE NOTE: 
Due to the COVID-19 virus pandemic  we have postponed our annual conference until further notice.

Please see twitter address @CCIConsortium for more information.
Thank you and stay well!

CCIC 2019 Annual Meeting Review

Immunotherapy has revolutionized the treatment of cancer, as PD-1 blockade and CAR-T cell therapies are becoming the standard of care in many disease settings.  However the field needs to learn much more about the basic biology of immunoregulation as well as the response and resistance mechanisms in patients to bring this to the next level.  Several topics that were highlighted include:​
  • Strategies to improve anti-tumor immunity
  • Insights into immunoregulation
  • Novel cell subsets
  • Autoimmunity as a consequence of PD-1 blockade
  • Insights from clinical trials
CCIC MISSION STATEMENT

Incorporation of immunotherapy into standards of care will require a new generation of basic and clinical scientists who are well-versed in tumor immunology, as well as an infrastructure capable of monitoring immune activity and treatment outcomes. To this end, the Canadian Cancer Immunotherapy Consortium (CCIC) formed in 2008 as a forum to bring together Canadian scientists and clinicians with interest in advancing clinical translation of cancer immunotherapy. The founding members of the CCIC are (from east to west) Réjean Lapointe, (Université de Montréal), Jonathan Bramson, (McMaster University), Pamela Ohashi, (Princess Margaret Cancer Centre) and Brad Nelson (BC Cancer).
 
The CCIC is an organization for the development, advancement and promotion of cancer immunotherapy in Canada, through 3 founding principles.
  • Interaction – exchange of information and education among basic researchers and clinicians. 
  • Innovation – develop and apply novel immune therapies. 
  • Leadership – provide guidance to integrate the Canadian landscape with global initiatives

The CCIC is committed to the advancement and training of young scientists and it is our vision that the organization will be pivotal in knowledge dissemination in order to raise the profile of Canadians in immunotherapy.
FOUNDING MEMBERS
Jonathan Bramson - McMaster University, Canada
Rejean Lapointe - University of Montreal, Canada
Brad Nelson - BC Cancer, Canada​
Pamela Ohashi - Tumor Immunotherapy Program, Princess Margaret Cancer Centre, Canada

PARTNERING ORGANIZATIONS/ INSTITUTIONS

13th Annual Canadian Cancer Immunotherapy Consortium - RESCHEDULED TO JUNE 2021

DATE: June 2021, at Hotel Chéribourg, Orford,  Quebec
LOCATION: Hotel Chéribourg, Orford,  Quebec
CANADIAN CANCER IMMUNOTHERAPY CONSORTIUM